Posts Tagged ‘reimbursement’

Insights from CGTW16 – Part 3: Clinical trials, health economics and regulatory affairs

Author: Guest, 12/01/16

Amin Adibi is a biomedical engineer and a research assistant at the University of British Columbia. His areas of interest include cell manufacturing and bioprocess optimization, clinical translation of cellular therapies, health outcomes and cost-effectiveness modelling. Amin has an MSc degree from University of Calgary, where he focused on developing adjuvant MSC-based therapies for brain…Read more

Making connections – advancing regenerative medicine through partnerships

Author: Nicole Forgione, 11/08/16

A key driver for advancements in regenerative medicine is partnerships. In recognition of this, every year CCRM hosts a networking reception that brings together our partners for an evening of discussion and knowledge sharing. This year’s industry networking reception was focused on the theme of increasing partnerships between industry and academia. I had the privilege…Read more

ISCT webinar: Reimbursement re-cap

Author: Mark Curtis, 12/28/15

For those of you that missed ISCT’s recent webinar on manufacturing, needle-to-needle logistics and reimbursement, below is a brief re-cap of the key points on the reimbursement section that I provided. The presentation, including audio, should be available free on the ISCT website shortly. Thanks again to ISCT for hosting and Invetech, a member of…Read more

Here we go…cells derived from embryonic stem cells in UK clinics

Author: David Kent, 11/16/15

The United Kingdom has begun its foray into using cells derived from human embryonic stem cells (ESCs) in clinical settings. I have to admit I was surprised that following coverage on the BBC and in The Guardian, there was virtually no anti-ESC protesting to be found, especially considering this was the first human ESC therapy…Read more

First gene therapy prescribed: How can we ensure there are more in the future?

Author: James Smith, 10/06/15

. With contributions from blogger David Brindley September 2015 has been an historic month for regenerative medicine. For the first time ever in the Western world, a prescription has been issued for a gene therapy, Glybera. At the ESGCT and FSGT Collaborative Congress, Helsinki, this news was welcomed and spurred discussion on broader challenges in…Read more

From bench to bedside: clinical trials and cancer drug approval in Canada

Author: Sara M. Nolte, 09/28/15

. Much of what we discuss here on Signals is what’s going on in the lab. I’ve definitely done my share of promoting basic science research in the cancer stem cell field (here and here). By now you, and almost everyone else, must be wondering why these “wonder drugs” aren’t being used yet. Well, it…Read more

Making sure amazing things happen

Author: Guest, 12/15/14

Joe Sornberger is Director of Communications Programs for the Canadian Stem Cell Foundation and author of the book “Dreams & Due Diligence: Till and McCulloch’s Stem Cell Discovery and Legacy.”   Amazing things can happen in 10 years. Consider the world, circa 2004. The United States had yet to elect an African American president, Steve…Read more

The value of a cure

Author: James Smith, 12/11/14

. With contributions from David Brindley. We recently discussed the role that consortia could play in accelerating the timeline of discovering and implementing new treatments, covering the ‘partnering’ aspect of the ‘Partnering for Cures’ conference held in New York City that was referenced. It, therefore, seems appropriate to devote some time to the ‘other half:’…Read more

Beta cell transplant, hype or hope?

Author: Mark Curtis, 12/04/14

. The Edmonton Protocol for the transplantation of insulin producing cells into individuals with type 1 diabetes (T1DM) has a cost per quality-adjusted life year (QALY) of ~$165,000. This is more than three times the willingness-to-pay (WTP) in Canada, and comfortably twice the WTP in the United States for many health care insurance plans. Even…Read more

Lessons from Dendreon

Author: Mark Curtis, 11/20/14

. You have all by now heard that Dendreon has filed for bankruptcy protection. If you’re a regular reader of Signals, you may have first heard the news here. While the company has successfully reached agreements on a financial restructuring with a majority of its senior debt holders, its fate remains unclear and could include…Read more